The problem posed by parallel importing causes consternation among leading British pharmaceutical industry executives. Indeed, the UK's industry lobby - the Association of the British Pharmaceutical Industry (ABPI) - recently issued a media briefing arguing that parallel importing could seriously damage the UK sector as well as posing hazards for patients. But a solution to the problem of parallel importing appears elusive.